Flatiron Health’s Post

Did you know that by participating in ICARE you may be able to contribute to other research efforts? For example, ICARE helps facilitate:  • A clinical trial that provides FREE resources to improve care in those with inherited cancer  • Genomic studies on tumor samples to better understand tumor development  • Other focused research efforts to help figure out cancer risks To learn more about participating in ICARE or if you'd like to enroll online, please visit https://lnkd.in/g9Xn6jZ. If you have any questions, please feel free to contact the ICARE team by phone (615-875-2444) or email ([email protected]). #ICARE #InheritedCancerRegistry #InheritedCancer #HereditaryCancer #Cancer #CancerGenetics #GeneticTesting #Genomics #TumorStudies #CancerRisks #CancerRiskManagement #CancerPrevention #CancerResearch #CancerEducation #CancerAwareness American Society of Clinical Oncology (ASCO) American Cancer Society National Cancer Institute (NCI) Vanderbilt Health VANDERBILT-INGRAM CANCER CENTER AT GREEN HILLS

Meet Digistain®, a game-changer in cancer diagnosis and a semi-finalist in this year’s EIT Health Catapult competition. Digistain aims to eliminate breast cancer care inequalities by transforming the speed, cost and accuracy of recurrence risk prediction. This biotech company takes the guesswork out of cancer diagnosis by measuring the chemical changes that accompany the disease, allowing physicians to decide who needs chemotherapy quickly and easily. Read more: https://lnkd.in/esV2Hj_b Hemmel Amrania PhD Breast Cancer Diagnostics Marc Butterly #cancercare #earlydiagnosis

#sponsored Unveiling the Power of Genomic Testing in Breast Cancer Treatment In the complex world of breast cancer diagnosis and treatment, genomic testing has emerged as a groundbreaking tool that is revolutionizing the way we approach this disease. At Learn Look Locate, we understand the importance of empowering patients with knowledge about the latest advancements in breast cancer care. In this blog post, we’ll delve into the fundamentals of genomic testing, exploring how it works and its crucial role in modern oncology. #genomics #breastcancerpatients #breastcancersurgery #breastcancer https://lnkd.in/eZruhGhJ

Debbie’s Dream Foundation: Curing Stomach Cancer is proud to present an insightful interview with Dr. Samuel Klempner, GI Medical Oncologist of Massachusetts General Hospital Cancer Center and Harvard Medical School, titled "Ask the Expert: The Role of Biomarkers in Stomach Cancer." In the first snippet from this Q&A, Dr. Klempner discusses the importance of biomarker testing in the diagnosis and treatment of stomach cancer. Understanding the role of biomarkers can help guide personalized treatment plans and improve patient outcomes. To watch the full interview, visit https://lnkd.in/ewuZ8iZF. #KnowYourBiomarkers #stomachcancer #GastricCancer #DebbiesDreamFoundation #CancerResearch #genetictesting #Her2positive #Brcagene #MSIgene

Want to learn more about improving access to clinical trial research? ACORI and its Research Review newsletter are here to keep you informed of the latest in cancer research innovations, actions, and issues. In this edition 🔗 https://bit.ly/3TMDjkY, learn about: •Unique challenges as younger populations are increasingly diagnosed with colorectal cancer • American Association for Cancer Research's inaugural 2023 conference discussion on recent advances in kidney cancer research • Carolina BioOncology Institute and BioCytics Inc's innovative work and their use of the Human Application Laboratory model • Flatiron Health's Clinical Pipe Tool and how it’s streamlining clinical trial research. •And more!

Exciting news in cancer diagnostics! Genoks Genetik Hastalıklar Değerlendirme Merkezi and Velsera have joined forces to revolutionize cancer care in Turkey and neighbouring regions. This strategic partnership combines Genoks' genomics expertise with Velsera's advanced Clinical Genomics Workspace (CGW). The CGW platform will enhance analysis of solid tissue, liquid tumours, and haematological cancer samples, empowering oncologists with precise insights. By integrating CGW into Genoks' diagnostic services, we're set to improve cancer detection and characterization. This collaboration promises to advance cancer research, elevate patient care standards, and provide more personalized treatment options. A significant step forward in the fight against cancer! https://lnkd.in/exQZcthm 📰 Stay ahead of the curve by following Practical Patient Care on LinkedIn for more industry news and insights. You can also access our latest edition here: https://lnkd.in/guUBWkRE #PracticalPatientCare #CancerDiagnostics #GenomicMedicine #HealthcareInnovation

Exciting insights and innovations emerging at ESMO Breast Cancer 2024! It's been inspiring to witness the cutting-edge research and clinical advancements showcased at this year's conference. From novel treatment modalities to predictive biomarkers, the future of breast cancer care is taking shape here. Grateful for the opportunity to stay informed and connected with leaders in the field. Looking forward to translating these learnings into meaningful improvements for patients. #ESMOBreastCancer #PrecisionMedicine #BreastCancerResearch

Exciting data presented by Dr. Andrew Nixon from Duke Cancer Institute and Dr. Fábio C. P. Navarro from Personalis at #ASCO24! In a study with 33 patients with metastatic esophagogastric cancer (mEGC) treated with pembrolizumab combined with oxaliplatin and capecitabine, NeXT Personal® demonstrated 100% baseline detection. Molecular progression based on ctDNA increases, consistently preceded imaging progression, with a median lead time of 55 days (~2 months). Patients exhibiting an early decrease or clearance in ctDNA levels showed significant improvement in overall survival (OS) (p-value=0.002 and 0.005, respectively) and progression-free survival (PFS) (p-value=0.005 and 0.012, respectively). These results are suggestive that an ultra-sensitive liquid biopsy platform could improve treatment decision-making for patients receiving ICB. Want to learn more about NeXT Personal? Visit us during ASCO at booth 30149. #PrecisionOncology #ctDNA #ImmunoTherapy

Did you know that by participating in ICARE you may be able to contribute to other research efforts? For example, ICARE helps facilitate:  • A clinical trial that provides FREE resources to improve care in those with inherited cancer  • Genomic studies on tumor samples to better understand tumor development  • Other focused research efforts to help figure out cancer risks To learn more about participating in ICARE or if you'd like to enroll online, please visit https://lnkd.in/g9Xn6jZ. If you have any questions, please feel free to contact the ICARE team by phone (615-875-2444) or email ([email protected]). #ICARE #InheritedCancerRegistry #InheritedCancer #HereditaryCancer #Cancer #CancerGenetics #GeneticTesting #Genomics #TumorStudies #CancerRisks #CancerRiskManagement #CancerPrevention #CancerResearch #CancerEducation #CancerAwareness American Society of Clinical Oncology (ASCO) American Cancer Society National Cancer Institute (NCI) Vanderbilt Health Vanderbilt-Ingram Cancer FORCE 

🤝 New Partnership- BostonGene and Sylvester Comprehensive Cancer Center! BostonGene partners with Sylvester Comprehensive Cancer Center at the University of Miami to validate blood- and bone-marrow based assays for hematologic cancers. In their first study together, researchers are comparing BostonGene's AI-powered platform to traditional methods for clinical testing in multiple myeloma patients. The collaboration aims to enhance diagnostic and prognostic strategies, paving the way for more personalized treatment approaches. Nathan Fowler, Chief Medical Officer at BostonGene, highlights the goal of revolutionizing cancer care towards tailored patient-specific solution- "Our goal is to fundamentally change how these cancers are diagnosed and managed, bringing us closer to a future where cancer care is precisely tailored to each patient's unique condition,". #CancerResearch #PrecisionMedicine #HealthcareCollaboration